HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jouko Levijoki Selected Research

N- (4- (4- methyl- 6- oxo- 1,4,5,6- tetrahydropyridazin- 3- yl)phenyl)acetamide (OR 1896)

5/2010Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jouko Levijoki Research Topics

Disease

8Heart Failure
12/2019 - 04/2008
5Myocardial Infarction
03/2016 - 10/2009
4Hypertrophy
12/2019 - 10/2009
4Fibrosis (Cirrhosis)
01/2012 - 01/2010
4Cardiomegaly (Heart Hypertrophy)
01/2012 - 05/2010
4Infarction (Infarctions)
11/2011 - 01/2010
3Ischemia
01/2016 - 06/2014
3Inflammation (Inflammations)
06/2015 - 05/2010
2Cardiac Arrhythmias (Arrythmia)
01/2021 - 01/2016
2Hypertension (High Blood Pressure)
06/2015 - 07/2011
2Type 2 Diabetes Mellitus (MODY)
01/2010 - 10/2009
1Myocardial Stunning (Stunned Myocardium)
03/2016
1Coronary Occlusion
03/2016
1Ventricular Premature Complexes (Premature Ventricular Contraction)
01/2016
1Ventricular Tachycardia
01/2016
1Renal Insufficiency (Renal Failure)
06/2015
1Stroke (Strokes)
03/2015
1Reperfusion Injury
06/2014
1Mitochondrial Diseases (Mitochondrial Disease)
01/2012
1Diabetic Cardiomyopathies
11/2011
1Neoplasms (Cancer)
11/2011
1Cardiovascular Diseases (Cardiovascular Disease)
07/2011

Drug/Important Bio-Agent (IBA)

7Simendan (Levosimendan)IBA
03/2016 - 04/2008
4CalciumIBA
11/2011 - 10/2009
3salicylhydroxamic acid (SHAM)IBA
06/2014 - 01/2010
3Angiotensin IIIBA
01/2012 - 10/2010
3Messenger RNA (mRNA)IBA
01/2012 - 05/2010
2ReninIBA
06/2015 - 10/2010
2AngiotensinogenIBA
06/2015 - 10/2010
2Adenosine Triphosphatases (ATPase)IBA
04/2013 - 07/2011
2phospholambanIBA
04/2013 - 07/2011
2Atrial Natriuretic Factor (ANF)IBA
01/2012 - 05/2010
2Potassium Channels (Potassium Channel)IBA
10/2010 - 10/2009
2Adenosine Triphosphate (ATP)IBA
10/2010 - 10/2009
1Brain Natriuretic Peptide (Natrecor)FDA Link
12/2019
1ORM-3819IBA
03/2016
1Sodium-Calcium ExchangerIBA
01/2016
1ORM-10962IBA
01/2016
1Ouabain (G Strophanthin)IBA
01/2016
1Monocyte Chemoattractant ProteinsIBA
06/2015
1Lipocalin-2IBA
06/2015
1Valsartan (Vals)FDA Link
03/2015
15- nitro- 2- (2- phenylchroman- 6- yloxy)pyridineIBA
10/2014
1NAD (NADH)IBA
10/2014
1DexmedetomidineFDA Link
06/2014
1Proteins (Proteins, Gene)FDA Link
04/2013
1Pharmaceutical PreparationsIBA
11/2011
1purineIBA
11/2011
1Peptides (Polypeptides)IBA
07/2011
1CollagenIBA
07/2011
1Sarcoplasmic Reticulum Calcium-Transporting ATPasesIBA
07/2011
1DiureticsIBA
07/2011
1Type 3 Cyclic Nucleotide PhosphodiesterasesIBA
10/2010
1Blood Glucose (Blood Sugar)IBA
05/2010
1N- (4- (4- methyl- 6- oxo- 1,4,5,6- tetrahydropyridazin- 3- yl)phenyl)acetamide (OR 1896)IBA
05/2010
1Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
05/2010
1Connective Tissue Growth FactorIBA
05/2010
1Sirtuin 1IBA
01/2010
1p38 Mitogen-Activated Protein KinasesIBA
01/2010

Therapy/Procedure

3Therapeutics
01/2021 - 03/2016
3Ligation
05/2010 - 10/2009
1Caloric Restriction
01/2012